구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzmab deruxtecan) Daiichi Sankyo / AstraZeneca·Gastric Cancer 56 trials |
|---|---|
Overview Program | T-Dxd(Trastuzmab deruxtecan), Ramucirumab |
Overview Company | Daiichi Sankyo / AstraZeneca |
Overview Modality | ADC |
Overview Target | Gastric Cancer |
Overview Indication | Gastric Cancer; Gastroesophageal Junction (GEJ) Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | DM1) and trastuzumab deruxtecan (T-DXd) usi |
MoA Mechanism | ADC uptake by alveolar macrophages through Fcγ receptors, followed by intracellular payload release and cytokine-mediated lung injury |
MoA Biomarker | HER2 expression |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | PK |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Interstitial lung disease was observed for both agents |
Clinical Safety signal | Interstitial lung disease was observed for both agents |
Clinical Selected reported efficacy | ORR 71.7% |
Clinical Reported ORR | 71.7% |
Clinical Result source | ClinicalTrials.gov NCT04739761 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT04739761 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzmab deruxtecan) Daiichi Sankyo / AstraZeneca·Gastric Cancer 56 trials |
|---|---|
Overview Program | T-Dxd(Trastuzmab deruxtecan), Ramucirumab |
Overview Company | Daiichi Sankyo / AstraZeneca |
Overview Modality | ADC |
Overview Target | Gastric Cancer |
Overview Indication | Gastric Cancer; Gastroesophageal Junction (GEJ) Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Payload | DM1) and trastuzumab deruxtecan (T-DXd) usi |
MoA Mechanism | ADC uptake by alveolar macrophages through Fcγ receptors, followed by intracellular payload release and cytokine-mediated lung injury |
MoA Biomarker | HER2 expression |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | PK |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Interstitial lung disease was observed for both agents |
Clinical Safety signal | Interstitial lung disease was observed for both agents |
Clinical Selected reported efficacy | ORR 71.7% |
Clinical Reported ORR | 71.7% |
Clinical Result source | ClinicalTrials.gov NCT04739761 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT04739761 |
추천 비교
추천 비교